Systematic review of epigenetic effects of pharmacological agents for bipolar disorders

Laura E. Lockwood, Nagy Adel Youssef

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Epigenetic effects of medications are an evolving field of medicine, and can change the landscape of drug development. The aim of this paper is to systematically review the literature of the relationship between common medications used for treatment of bipolar disorders and epigenetic modifications. MedLine/PubMed searches were performed based on pre-specified inclusion criteria frominception toNovember 2017. Six animal and human studiesmet the inclusion criteria. These studies examined the epigenetic changes in the main classes of medications that are used in bipolar disorders, namely mood stabilizers and antipsychotics. Although these initial studies have small to moderate sample size, they generally suggest an evolving and accumulating evidence of epigenetic changes that are associated with several of the medications that are used in bipolar I and II disorders. In this manuscript, we describe the specific epigenetic changes that are associated with the medications studied. Of the studies reviewed, five of the six studies revealed epigenetic changes associated with the use of mood stabilizers or antipsychotic medications. This review contributes to future research directions. Further understanding of the complexities of the epigenome and the untangling of the effects and contributions of disease states versus medications is crucial for the future of drug design and the development of new therapeutics. Epigenetic therapeutics hold great promise for complex disease treatment and personalized interventions, including psychiatric diseases.

Original languageEnglish (US)
Article number154
JournalBrain Sciences
Volume7
Issue number11
DOIs
StatePublished - Nov 18 2017

Fingerprint

Bipolar Disorder
Epigenomics
Pharmacology
Antipsychotic Agents
Drug Design
PubMed
Sample Size
Psychiatry
Medicine
Therapeutics
Pharmaceutical Preparations

Keywords

  • Antipsychotics
  • Bipolar disorders
  • Drug development
  • Epigenetics
  • Epigenomics
  • Mood disorders
  • Mood stabilizers

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Systematic review of epigenetic effects of pharmacological agents for bipolar disorders. / Lockwood, Laura E.; Youssef, Nagy Adel.

In: Brain Sciences, Vol. 7, No. 11, 154, 18.11.2017.

Research output: Contribution to journalReview article

@article{562a78059e4a4642b7ebf8434d26d1d5,
title = "Systematic review of epigenetic effects of pharmacological agents for bipolar disorders",
abstract = "Epigenetic effects of medications are an evolving field of medicine, and can change the landscape of drug development. The aim of this paper is to systematically review the literature of the relationship between common medications used for treatment of bipolar disorders and epigenetic modifications. MedLine/PubMed searches were performed based on pre-specified inclusion criteria frominception toNovember 2017. Six animal and human studiesmet the inclusion criteria. These studies examined the epigenetic changes in the main classes of medications that are used in bipolar disorders, namely mood stabilizers and antipsychotics. Although these initial studies have small to moderate sample size, they generally suggest an evolving and accumulating evidence of epigenetic changes that are associated with several of the medications that are used in bipolar I and II disorders. In this manuscript, we describe the specific epigenetic changes that are associated with the medications studied. Of the studies reviewed, five of the six studies revealed epigenetic changes associated with the use of mood stabilizers or antipsychotic medications. This review contributes to future research directions. Further understanding of the complexities of the epigenome and the untangling of the effects and contributions of disease states versus medications is crucial for the future of drug design and the development of new therapeutics. Epigenetic therapeutics hold great promise for complex disease treatment and personalized interventions, including psychiatric diseases.",
keywords = "Antipsychotics, Bipolar disorders, Drug development, Epigenetics, Epigenomics, Mood disorders, Mood stabilizers",
author = "Lockwood, {Laura E.} and Youssef, {Nagy Adel}",
year = "2017",
month = "11",
day = "18",
doi = "10.3390/brainsci7110154",
language = "English (US)",
volume = "7",
journal = "Brain Sciences",
issn = "2076-3425",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - Systematic review of epigenetic effects of pharmacological agents for bipolar disorders

AU - Lockwood, Laura E.

AU - Youssef, Nagy Adel

PY - 2017/11/18

Y1 - 2017/11/18

N2 - Epigenetic effects of medications are an evolving field of medicine, and can change the landscape of drug development. The aim of this paper is to systematically review the literature of the relationship between common medications used for treatment of bipolar disorders and epigenetic modifications. MedLine/PubMed searches were performed based on pre-specified inclusion criteria frominception toNovember 2017. Six animal and human studiesmet the inclusion criteria. These studies examined the epigenetic changes in the main classes of medications that are used in bipolar disorders, namely mood stabilizers and antipsychotics. Although these initial studies have small to moderate sample size, they generally suggest an evolving and accumulating evidence of epigenetic changes that are associated with several of the medications that are used in bipolar I and II disorders. In this manuscript, we describe the specific epigenetic changes that are associated with the medications studied. Of the studies reviewed, five of the six studies revealed epigenetic changes associated with the use of mood stabilizers or antipsychotic medications. This review contributes to future research directions. Further understanding of the complexities of the epigenome and the untangling of the effects and contributions of disease states versus medications is crucial for the future of drug design and the development of new therapeutics. Epigenetic therapeutics hold great promise for complex disease treatment and personalized interventions, including psychiatric diseases.

AB - Epigenetic effects of medications are an evolving field of medicine, and can change the landscape of drug development. The aim of this paper is to systematically review the literature of the relationship between common medications used for treatment of bipolar disorders and epigenetic modifications. MedLine/PubMed searches were performed based on pre-specified inclusion criteria frominception toNovember 2017. Six animal and human studiesmet the inclusion criteria. These studies examined the epigenetic changes in the main classes of medications that are used in bipolar disorders, namely mood stabilizers and antipsychotics. Although these initial studies have small to moderate sample size, they generally suggest an evolving and accumulating evidence of epigenetic changes that are associated with several of the medications that are used in bipolar I and II disorders. In this manuscript, we describe the specific epigenetic changes that are associated with the medications studied. Of the studies reviewed, five of the six studies revealed epigenetic changes associated with the use of mood stabilizers or antipsychotic medications. This review contributes to future research directions. Further understanding of the complexities of the epigenome and the untangling of the effects and contributions of disease states versus medications is crucial for the future of drug design and the development of new therapeutics. Epigenetic therapeutics hold great promise for complex disease treatment and personalized interventions, including psychiatric diseases.

KW - Antipsychotics

KW - Bipolar disorders

KW - Drug development

KW - Epigenetics

KW - Epigenomics

KW - Mood disorders

KW - Mood stabilizers

UR - http://www.scopus.com/inward/record.url?scp=85036521178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036521178&partnerID=8YFLogxK

U2 - 10.3390/brainsci7110154

DO - 10.3390/brainsci7110154

M3 - Review article

VL - 7

JO - Brain Sciences

JF - Brain Sciences

SN - 2076-3425

IS - 11

M1 - 154

ER -